OR WAIT null SECS
© 2021 MJH Life Sciences and Modern Retina. All rights reserved.
© 2021 MJH Life Sciences™ and Modern Retina. All rights reserved.
May 07, 2021
Michael A. Singer, MD, speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).
May 03, 2021
Logan Vander Woude, DO, MPH, examines research on improved resolution of symptomatic vitreomacular traction as an attempt to further refine the potential factors predictive of better outcomes.
Glenn J. Jaffe, MD, discusses the key points of his virtual presentation on targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised, and the need for newer treatment therapies to target different pathways.
Robyn Guymer, PhD, MBBS, highlights the latest trial results for faricimab, the first bispecific antibody designed for intraocular use in treating patients with neovascular age-related macular degeneration.
May 02, 2021
Investigators offer insight on how patients with BRVO or CRVO with any lapse in treatment of 3 months or longer are at risk for poorer outcomes.
April 23, 2021
Community support and research continue to boost treatment in children
April 16, 2021
Studies are uncovering a range of potential treatment options for disorders
April 14, 2021
How a combined ophthalmology/rheumatology uveitis clinic collaborates to monitor systemic disease activity and tolerance to systemic therapy
April 07, 2021
Worldwide increase in technologies for ophthalmic use is dramatic
April 06, 2021
Fluocinolone acetonide implant for DME benefits visual acuity